Coronavirus (COVID-19) Q&A

4.3 (105)
MEDICINE

Conversations with experts and frontline clinicians about the COVID-19 pandemic, hosted by editors from the JAMA Network.

APR 29

Association of New-Onset Seizures With SARS-CoV-2 Vaccines

Interview with Churl-Su Kwon, MD, MPH, author of Association of New-Onset Seizures With SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Hosted by Cynthia E. Armand, MD. Related Content: Association of New-Onset Seizures With SARS-CoV-2 Vaccines

17 min
APR 5

Measuring Medicaid Enrollment More Accurately to Guide Post–COVID-19 Pandemic Policy

Benjamin D. Sommers, MD, PhD, of Harvard University, speaks with JAMA Health Forum Editor John Ayanian, MD, MPP, and Deputy Editor Melinda Buntin, PhD, about differences in Medicaid enrollment as measured in surveys and administrative data. These differences have implications for estimating coverage now that the federal policy of continuous Medicaid eligibility during the COVID-19 pandemic has ended. Related Content: Survey-Reported Coverage in 2019-2022 and Implications for Unwinding Medicaid Continuous Eligibility

19 min
MAR 1

February 2024 Medical News Summary

Rural Maternity Care Is in Crisis—Here’s What Could Help; Type and Severity of Immunodeficiency Affect Speed of SARS-CoV-2 Clearance, Study Finds Related Content: More Than Half of US Rural Hospitals No Longer Offer Birthing Services—Here’s Why When It Comes to SARS-CoV-2 Clearance, People Who Are Immunocompromised Are Not All Alike

14 min
FEB 6

Evaluating the Effectiveness of Bivalent COVID-19 Vaccines in Children and Adolescents

Bivalent mRNA COVID-19 vaccines were recommended for children and adolescents aged 5 to 17 years in the US, but were they effective? JAMA Associate Editor Tracy A. Lieu, MD, MPH, spoke with author Leora R. Feldstein, PhD, US Centers for Disease Control and Prevention, about the effectiveness of bivalent COVID-19 vaccines in children and adolescents. Related Content: Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years

12 min
FEB 2

Changes in Access to Care and Preventive Services by Race and Ethnicity During the COVID-19 Pandemic

The COVID-19 pandemic has caused major disruptions in ambulatory care. In this interview with JAMA Health Forum Editor John Ayanian, MD, MPP, and Deputy Editor Melinda Buntin, PhD, Rishi K. Wadhera, MD, MPP, MPhil, of Harvard Medical School discusses how access to care and preventive services changed for different racial and ethnic groups in the US from 2019 to 2022. Related Content: Changes in Health Care Access and Preventive Health Screenings by Race and Ethnicity

14 min
JAN 22

Safety and Effectiveness of Maternal and Child COVID-19 Vaccination

Two recent studies find that COVID-19 vaccination during pregnancy is safe for infants and effective for children aged 1-4 years. JAMA Pediatrics Editor in Chief Dimitri Christakis, MD, and JAMA Pediatrics Associate Editor Alison Galbraith, MD, discuss clinical and policy implications with Grace Lee, MD, MPH, professor of Pediatrics at Stanford University School of Medicine, Palo Alto, California. Related Content: Newborn and Early Infant Outcomes Following Maternal COVID-19 Vaccination During Pregnancy Effectiveness of Monovalent mRNA Vaccines Against Omicron XBB Infection in Singaporean Children Younger Than 5 Years

20 min
09/26/2023

The Connection Between SARS-CoV-2 and Type 1 Diabetes Risk in Young Children

During the COVID-19 pandemic, the incidence of diabetes in childhood increased. JAMA Associate Editor Anne R. Cappola, MD, ScM, and Ezio Bonifacio, PhD, from the Center for Regenerative Therapies at the Dresden University of Technology, discuss SARS-CoV-2 infection and its association with islet autoimmunity in early childhood. Related Content: SARS-CoV-2 Infection and Development of Islet Autoimmunity in Early Childhood

15 min
09/21/2023

Efficacy of Gabapentin For Post–COVID-19 Olfactory Dysfunction

Interview with Jay F. Piccirillo, MD, author of Efficacy of Gabapentin For Post–COVID-19 Olfactory Dysfunction: The GRACE Randomized Clinical Trial. Hosted by Paul C. Bryson, MD, MBA. Related Content: Efficacy of Gabapentin For Post–COVID-19 Olfactory Dysfunction

14 min

See All (225)

4.3

out of 5

105 Ratings

Highly Recommend

02/24/2021

sal2211

Superior, excellent, interesting and amazing questions asked. This is an engaging Podcast! Highly recommend!
Bauchner, please watch the sexist language

02/24/2021

yohoyoohoo

Bauchner, during your interview with Wollenski, why would you ask her how her kids are responding to her heading the CDC? Is this a question that you ask CDC directors who are men, also? I’m glad that Wollenski answered that question with grace.
Dr Fauci

02/05/2021

Ginagina Smith

Love him!
Great podcast

01/13/2021

neffuchadnezzar

I truly enjoy the information JAMA provides to a lay audience. One thing I’d critique is that while the general public is often ignorant or detached from science/scientists, the inverse is also true and isn’t often addressed in these conversations.